ChronoScale AI Stock Analysis
ChronoScale (23E1) AI Stock Analysis
ChronoScale
(Frankfurt:23E1)
No summary available
ChronoScale (23E1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 33.46M
- Dividend Yield
- ―
- Average Volume (3M)
- 4
- Price to Earnings (P/E)
- ―
- Beta (1Y)
- 1.92
- Revenue Growth
- 170.45%
- EPS Growth
- 53.55%
- Country
- Germany
- Employees
- 86
- Sector
- Technology
- Sector Strength
- 61
- Industry
- Information Technology Services
ChronoScale Business Overview & Revenue Model
Company Description
ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and...
ChronoScale Earnings Call Summary
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.
ChronoScale Risk Analysis
ChronoScale disclosed 60 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksChronoScale Peers Comparison
Overall Rating
HBIO52Neutral
MLSS44Neutral
LUCY42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 61Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
| 52Neutral | $40.75M | -3.47 | -130.06% | ― | 2.34% | 78.52% | |
| 44Neutral | $26.64M | -7.03 | -122.29% | ― | 3.93% | 48.18% | |
| 42Neutral | $6.81M | -0.63 | -102.66% | ― | 56.89% | 52.61% |
* Technology Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:23E1 | Chronoscale Corporation | 8.61 | 5.29 | 159.73% | |
| HBIO | Harvard Bioscience | 9.08 | 2.88 | 46.52% | |
| MLSS | Milestone Scientific Inc | 0.28 | -0.04 | -13.44% | |
| LUCY | Innovative Eyewear, Inc. | 0.77 | -0.83 | -51.75% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
